MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- BIOCON
- BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5%
BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5%
Mon, 29 Jul
BIOCON has announced its results for the quarter ended June 2019. Here is a detailed performance review of the same:
BIOCON Quarterly Financials
| No. of Mths Qtr. Ending | 3 Jun-18* | 3 Mar-19* | 3 Jun-19* | QoQ Change | YoY Change | |
|---|---|---|---|---|---|---|
| Net Sales | Rs m | 11,238 | 7,639 | 4,808 | -37.1% | -57.2% |
| Other income | Rs m | 688 | 139 | 253 | 82.0% | -63.2% |
| Turnover | Rs m | 11,926 | 7,778 | 5,061 | -34.9% | -57.6% |
| Expenses | Rs m | 8,860 | 6,654 | 4,074 | -38.8% | -54.0% |
| Gross profit | Rs m | 2,378 | 985 | 1,554 | 57.8% | -34.7% |
| Depreciation | Rs m | 991 | 375 | 240 | -36.0% | -75.8% |
| Interest | Rs m | 176 | 6 | 5 | -16.7% | -97.2% |
| Profit before tax | Rs m | 1,899 | 743 | 1,562 | 110.2% | -17.7% |
| Tax | Rs m | 521 | 38 | 342 | 800.0% | -34.4% |
| Profit after tax | Rs m | 1,378 | 705 | 1,220 | 73.0% | -11.5% |
| Gross profit margin | % | 21.2 | 12.9 | 32.3 | ||
| Effective tax rate | % | 27.4 | 5.1 | 21.9 | ||
| Net profit margin | % | 11.6 | 9.1 | 24.1 |
Interim results exclude extraordinary / exceptional items
Year-on-Year Performance:
- The company's operating income during the quarter fell 57.2% on a year-on-year (YoY) basis. The expenses were down by 54.0% YoY during the same period.
- The company's operating profit declined by 34.7% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 32.3% in 1QFY20 as against 21.2% in 1QFY19.
- Depreciation charges declined by 75.8% and finance costs declined by 97.2% YoY, respectively.
- Other income declined by 63.2% YoY during the quarter.
- Net profit for the quarter declined by 11.5% YoY. Net profit margins during the quarter increased from 11.6% in 1QFY19 to 24.1% in 1QFY20.
Quarter-on-Quarter Performance:
- The company's operating income during the quarter fell 37.1% on a quarter-on-quarter (QoQ) basis. The expenses were down by 38.8% QoQ during the same period.
- The company's operating profit increased by 57.8% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 32.3% in 1QFY20 as against 12.9% in 4QFY19.
- Net profit for the quarter increased by 73.0% QoQ, while net profit margins increased from 9.1% in 4QFY19 to 24.1% in 1QFY20.
To see how BIOCON has performed over the last eight quarters,please visit here.
BIOCON Share Price Performance
Over the last one year,BIOCON share price has moved down from Rs 293.4 to Rs 236.8, registering a Loss of Rs 56.6 or around 19.3%.
Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 12,774.7 (down 1.4%). Over the last one year it has moved down from 14,027.7 to 12,774.7, a gain of 1,253 points (down 8.9%).
Overall, the S&P BSE SENSEX is up 1.7% over the year.
Current Valuations
At the current price of Rs 236.8, the price to earnings (P/E) ratio of BIOCON stands at 17.7 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 2.7 times.
|
| |
Related Views on News
BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)
Apr 26, 2019 | Updated on Apr 26, 2019For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)
Jan 28, 2019 | Updated on Jan 28, 2019For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.
Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)
Feb 2, 2018Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)
Oct 14, 2019This is once in a decade opportunity to make a killing from smallcap rebound.
Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)
Oct 7, 2019Here's what every individual investor must know about Yes Bank...
What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)
Oct 1, 2019How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?
The One Stock I Like in this Market(The 5 Minute Wrapup)
Oct 10, 2019There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?
5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)
Oct 11, 2019Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.
More|
| |
BIOCON SHARE PRICE
Oct 14, 2019 (Close)
TRACK BIOCON
- Track your investment in BIOCON with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON BIOCON
BIOCON 5-YR ANALYSIS
COMPARE BIOCON WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster requests your view! Post a comment on "BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!